A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: D-2570 Tablet, Placebo Tablets.
- Who it may be relevant to
- Registry conditions: Psoriasis. Basic parameters: 18 years — 70 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Participants With Moderate to Severe Plaque Psoriasis
Overview
A Study looking at the safety and efficacy of D-2570 in Participants with Plaque Psoriasis
Detailed description
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Participants with Moderate to Severe Plaque Psoriasis
Interventions
- Drug D-2570 Tablet
Active Treatment - Drug Placebo Tablets
Identical Tablet
Primary outcome measures
- Improvement in PASI-90 [Time frame: Assessment completed after 12 weeks of treatment/placebo]
Eligibility criteria
Inclusion criteria
- Participants with a diagnosis of plaque psoriasis with no significant flares of disease activity for at least 6 months before signing the informed consent
- Participants have moderate to severe plaque psoriasis as defined by a total body surface area (BSA) ≥10%, a Psoriasis Area and Severity Index (PASI) score ≥ 12 and a Physician's Global Assessment (PGA) score ≥ 3.
- Within normal ranges of laboratory assessments
Exclusion criteria
- Any comorbidities or past medical conditions as outlined in the protocol that would interfere with study assessments as deemed by the Investigator
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Quadruple blind
- Primary purpose
- Treatment
Study locations
United States · 20 centers
- Study Center — Birmingham
- Study Center — Phoenix
- Study Center — Chula Vista
- Study Center — Fountain Valley
- Study Center — Fremont
- Study Center — Los Angeles
- Study Center — Los Angeles
- Study Center — San Diego
- … and 12 more centers
Identifiers
NCT: NCT07489885 · D2570-207